{"id":"https://openalex.org/W2139291133","doi":"https://doi.org/10.1158/1535-7163.mct-09-0938","title":"The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106","display_name":"The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106","alternate_titles":[],"publication_year":2010,"publication_date":"2010-01-01","ids":{"openalex":"https://openalex.org/W2139291133","doi":"https://doi.org/10.1158/1535-7163.mct-09-0938","mag":"2139291133","pmid":"https://pubmed.ncbi.nlm.nih.gov/20053762"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.mct-09-0938","doi":"https://doi.org/10.1158/1535-7163.mct-09-0938","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-09-0938","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2139291133"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5091648628","display_name":"Michael I. Walton","orcid":"https://orcid.org/0000-0002-3782-0032","observed_orcids":["https://orcid.org/0000-0002-3782-0032"]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]},{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Michael I. Walton","raw_affiliation_strings":["Authors' Affiliations:\u20081Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom and 2Sareum Ltd, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom and 2Sareum Ltd, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I142947616","https://openalex.org/I2801316944"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112904632","display_name":"Paul D. Eve","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]},{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Paul D. Eve","raw_affiliation_strings":["Authors' Affiliations:\u20081Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom and 2Sareum Ltd, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom and 2Sareum Ltd, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I142947616","https://openalex.org/I2801316944"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061423488","display_name":"Angela Hayes","orcid":"https://orcid.org/0000-0001-6788-5761","observed_orcids":["https://orcid.org/0000-0001-6788-5761"]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]},{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Angela Hayes","raw_affiliation_strings":["Authors' Affiliations:\u20081Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom and 2Sareum Ltd, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom and 2Sareum Ltd, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I142947616","https://openalex.org/I2801316944"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089603827","display_name":"Melanie R. Valenti","orcid":"https://orcid.org/0000-0001-7610-1375","observed_orcids":["https://orcid.org/0000-0001-7610-1375"]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]},{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Melanie Valenti","raw_affiliation_strings":["Authors' Affiliations:\u20081Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom and 2Sareum Ltd, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom and 2Sareum Ltd, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I142947616","https://openalex.org/I2801316944"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112904367","display_name":"Alexis de Haven Brandon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]},{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Alexis De Haven Brandon","raw_affiliation_strings":["Authors' Affiliations:\u20081Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom and 2Sareum Ltd, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom and 2Sareum Ltd, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I142947616","https://openalex.org/I2801316944"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110967569","display_name":"Gary Box","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]},{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Gary Box","raw_affiliation_strings":["Authors' Affiliations:\u20081Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom and 2Sareum Ltd, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom and 2Sareum Ltd, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I142947616","https://openalex.org/I2801316944"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109601907","display_name":"Kathy J. Boxall","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]},{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Kathy J. Boxall","raw_affiliation_strings":["Authors' Affiliations:\u20081Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom and 2Sareum Ltd, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom and 2Sareum Ltd, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I142947616","https://openalex.org/I2801316944"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019001132","display_name":"G. Wynne Aherne","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]},{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"G. Wynne Aherne","raw_affiliation_strings":["Authors' Affiliations:\u20081Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom and 2Sareum Ltd, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom and 2Sareum Ltd, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I142947616","https://openalex.org/I2801316944"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110523635","display_name":"Suzanne A. Eccles","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]},{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Suzanne A. Eccles","raw_affiliation_strings":["Authors' Affiliations:\u20081Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom and 2Sareum Ltd, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom and 2Sareum Ltd, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I142947616","https://openalex.org/I2801316944"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058014829","display_name":"Florence I. Raynaud","orcid":"https://orcid.org/0000-0003-0957-6279","observed_orcids":["https://orcid.org/0000-0003-0957-6279"]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]},{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Florence I. Raynaud","raw_affiliation_strings":["Authors' Affiliations:\u20081Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom and 2Sareum Ltd, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom and 2Sareum Ltd, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I142947616","https://openalex.org/I2801316944"]}]},{"author_position":"middle","author":{"id":null,"display_name":"David H. Williams","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]},{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"David H. Williams","raw_affiliation_strings":["Authors' Affiliations:\u20081Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom and 2Sareum Ltd, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom and 2Sareum Ltd, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I142947616","https://openalex.org/I2801316944"]}]},{"author_position":"middle","author":{"id":null,"display_name":"John C. Reader","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]},{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"John C. Reader","raw_affiliation_strings":["Authors' Affiliations:\u20081Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom and 2Sareum Ltd, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom and 2Sareum Ltd, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I142947616","https://openalex.org/I2801316944"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007384881","display_name":"Ian Collins","orcid":"https://orcid.org/0000-0002-8143-8498","observed_orcids":["https://orcid.org/0000-0002-8143-8498"]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]},{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Ian Collins","raw_affiliation_strings":["Authors' Affiliations:\u20081Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom and 2Sareum Ltd, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom and 2Sareum Ltd, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I142947616","https://openalex.org/I2801316944"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5015193618","display_name":"Michelle Dawn Garrett","orcid":"https://orcid.org/0000-0002-3939-1673","observed_orcids":["https://orcid.org/0000-0002-3939-1673"]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]},{"id":"https://openalex.org/I2801316944","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67","country_code":"GB","type":"nonprofit","lineage":["https://openalex.org/I2801316944"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Michelle D. Garrett","raw_affiliation_strings":["Authors' Affiliations:\u20081Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom and 2Sareum Ltd, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom and 2Sareum Ltd, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I142947616","https://openalex.org/I2801316944"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5091648628"],"corresponding_institution_ids":["https://openalex.org/I142947616","https://openalex.org/I2801316944"],"apc_list":null,"apc_paid":null,"fwci":4.6849,"has_fulltext":false,"cited_by_count":110,"citation_normalized_percentile":{"value":0.9641202,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":91,"max":99},"biblio":{"volume":"9","issue":"1","first_page":"89","last_page":"100"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10123","display_name":"DNA Repair Mechanisms","score":0.7925000190734863,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10123","display_name":"DNA Repair Mechanisms","score":0.7925000190734863,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.12929999828338623,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10583","display_name":"Cancer-related Molecular Pathways","score":0.0284000001847744,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chk1-inhibitor","display_name":"CHK1 inhibitor","score":0.9660000205039978},{"id":"https://openalex.org/keywords/dna-damage-checkpoint","display_name":"DNA damage checkpoint","score":0.49900001287460327},{"id":"https://openalex.org/keywords/p53-deficient-tumors","display_name":"p53-deficient tumors","score":0.7480000257492065},{"id":"https://openalex.org/keywords/etoposide","display_name":"etoposide","score":0.6890000104904175},{"id":"https://openalex.org/keywords/gemcitabine","display_name":"gemcitabine","score":0.9819999933242798},{"id":"https://openalex.org/keywords/sn-38","display_name":"SN-38","score":0.8209999799728394},{"id":"https://openalex.org/keywords/irinotecan","display_name":"irinotecan","score":0.9800000190734863},{"id":"https://openalex.org/keywords/cdk1-phosphorylation","display_name":"CDK1 phosphorylation","score":0.7850000262260437},{"id":"https://openalex.org/keywords/gamma-h2ax","display_name":"\u03b3H2AX","score":0.8379999995231628},{"id":"https://openalex.org/keywords/parp-cleavage","display_name":"PARP cleavage","score":0.9390000104904175},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.5799999833106995},{"id":"https://openalex.org/keywords/colon-cancer","display_name":"colon cancer","score":0.8109999895095825}],"concepts":[{"id":"https://openalex.org/C50001416","wikidata":"https://www.wikidata.org/wiki/Q17861750","display_name":"CHEK1","level":5,"score":0.8328676223754883},{"id":"https://openalex.org/C143425029","wikidata":"https://www.wikidata.org/wiki/Q5205747","display_name":"DNA damage","level":3,"score":0.676606297492981},{"id":"https://openalex.org/C54086632","wikidata":"https://www.wikidata.org/wiki/Q5512671","display_name":"G2-M DNA damage checkpoint","level":5,"score":0.5765454769134521},{"id":"https://openalex.org/C120504264","wikidata":"https://www.wikidata.org/wiki/Q1147372","display_name":"Cyclin-dependent kinase 1","level":4,"score":0.5573997497558594},{"id":"https://openalex.org/C105696609","wikidata":"https://www.wikidata.org/wiki/Q1068809","display_name":"Cell cycle checkpoint","level":4,"score":0.5165532827377319},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.4670155644416809},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.4531481862068176},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4161294102668762},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.40887293219566345},{"id":"https://openalex.org/C29537977","wikidata":"https://www.wikidata.org/wiki/Q188941","display_name":"Cell cycle","level":3,"score":0.38983914256095886},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.17963621020317078},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.1589277982711792},{"id":"https://openalex.org/C552990157","wikidata":"https://www.wikidata.org/wiki/Q7430","display_name":"DNA","level":2,"score":0.12339335680007935},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000071877","descriptor_name":"Checkpoint Kinase 1","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077146","descriptor_name":"Irinotecan","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000093542","descriptor_name":"Gemcitabine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D002166","descriptor_name":"Camptothecin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D002166","descriptor_name":"Camptothecin","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D002166","descriptor_name":"Camptothecin","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D003841","descriptor_name":"Deoxycytidine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003841","descriptor_name":"Deoxycytidine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D003841","descriptor_name":"Deoxycytidine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D004249","descriptor_name":"DNA Damage","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004357","descriptor_name":"Drug Synergism","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007546","descriptor_name":"Isoquinolines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007546","descriptor_name":"Isoquinolines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D007546","descriptor_name":"Isoquinolines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D007546","descriptor_name":"Isoquinolines","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D008819","descriptor_name":"Mice, Nude","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009153","descriptor_name":"Mutagens","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D010766","descriptor_name":"Phosphorylation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D011494","descriptor_name":"Protein Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D014408","descriptor_name":"Biomarkers, Tumor","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D016195","descriptor_name":"G2 Phase","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D016923","descriptor_name":"Cell Death","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1158/1535-7163.mct-09-0938","doi":"https://doi.org/10.1158/1535-7163.mct-09-0938","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-09-0938","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},{"id":"pmid:20053762","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20053762","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular cancer therapeutics","raw_type":"Journal Article"},{"id":"pmh:oai:kar.kent.ac.uk:58575","doi":null,"is_oa":false,"landing_page_url":"https://kar.kent.ac.uk/58575/","pdf_url":null,"source":{"id":"https://openalex.org/S4377196264","display_name":"Kent Academic Repository (University of Kent)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I20581793","host_organization_name":"University of Kent","host_organization_lineage":["https://openalex.org/I20581793"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.8560000061988831,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G513727605","display_name":null,"funder_award_id":"C309/A8274","funder_id":"https://openalex.org/F4320319985","funder_display_name":"Cancer Research UK"}],"funders":[{"id":"https://openalex.org/F4320319985","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67"},{"id":"https://openalex.org/F4320319990","display_name":"National Institute for Health and Care Research","ror":"https://ror.org/0187kwz08"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":48,"referenced_works":["https://openalex.org/W1524628399","https://openalex.org/W1752089945","https://openalex.org/W1840165714","https://openalex.org/W1903850103","https://openalex.org/W1966956946","https://openalex.org/W1970858010","https://openalex.org/W1970963436","https://openalex.org/W1974788629","https://openalex.org/W1984537002","https://openalex.org/W1985775217","https://openalex.org/W1988443306","https://openalex.org/W1991054314","https://openalex.org/W2023942118","https://openalex.org/W2029080338","https://openalex.org/W2030288839","https://openalex.org/W2037356096","https://openalex.org/W2041680250","https://openalex.org/W2042316019","https://openalex.org/W2048451721","https://openalex.org/W2049856484","https://openalex.org/W2054576158","https://openalex.org/W2076314401","https://openalex.org/W2076324577","https://openalex.org/W2079017691","https://openalex.org/W2085908746","https://openalex.org/W2087476908","https://openalex.org/W2095986441","https://openalex.org/W2097173890","https://openalex.org/W2104903083","https://openalex.org/W2105768236","https://openalex.org/W2106141758","https://openalex.org/W2109689528","https://openalex.org/W2111403239","https://openalex.org/W2111546308","https://openalex.org/W2112481873","https://openalex.org/W2128252882","https://openalex.org/W2133999831","https://openalex.org/W2145339037","https://openalex.org/W2146274229","https://openalex.org/W2148958834","https://openalex.org/W2151180466","https://openalex.org/W2153635460","https://openalex.org/W2162730779","https://openalex.org/W2416730013","https://openalex.org/W2417202149","https://openalex.org/W2435272102","https://openalex.org/W2479044294","https://openalex.org/W6682703413"],"related_works":["https://openalex.org/W2067339414","https://openalex.org/W2074692995","https://openalex.org/W2036522505","https://openalex.org/W2155205362","https://openalex.org/W2180047772","https://openalex.org/W3188421389","https://openalex.org/W2067958256","https://openalex.org/W2063393084","https://openalex.org/W2106622937","https://openalex.org/W2488349910"],"abstract_inverted_index":{"Genotoxic":[0],"antitumor":[1,212,234],"agents":[2],"continue":[3],"to":[4,48,139],"be":[5,71],"the":[6,27,49,74,107,130,169,201],"mainstay":[7],"of":[8,29,103,121,133,163,171,228],"current":[9],"cancer":[10],"chemotherapy.":[11],"These":[12],"drugs":[13,239],"cause":[14],"DNA":[15,24,84,203],"damage":[16,204],"and":[17,26,38,53,87,96,127,135,148,167,182,193,205,210,242],"activate":[18],"numerous":[19],"cell":[20,61,131,207],"cycle":[21],"checkpoints":[22],"facilitating":[23],"repair":[25],"maintenance":[28],"genomic":[30],"integrity.":[31],"Most":[32],"human":[33,109],"tumors":[34],"lack":[35],"functional":[36],"p53":[37],"consequently":[39],"have":[40,155,245],"compromised":[41],"G(1)-S":[42,75],"checkpoint":[43,55,89],"control.":[44,90],"This":[45,111],"has":[46],"led":[47],"hypothesis":[50],"that":[51,157,231],"S":[52,86],"G(2)-M":[54,88],"abrogation":[56],"may":[57,243],"selectively":[58],"enhance":[59,233],"genotoxic":[60],"killing":[62,132],"in":[63,124,141,146,149,175,180,183,218,240],"a":[64,79,150,176,225],"p53-deficient":[65],"background,":[66],"as":[67],"normal":[68],"cells":[69],"would":[70],"rescued":[72],"at":[73,165,173],"checkpoint.":[76],"CHK1":[77,98,164,229],"is":[78,92],"serine/threonine":[80],"kinase":[81],"associated":[82,189],"with":[83,100,118,190,200,220,236],"damage-linked":[85],"SAR-020106":[91,158,217,223],"an":[93,101,114,119],"ATP-competitive,":[94],"potent,":[95],"selective":[97],"inhibitor":[99],"IC(50)":[102,120],"13.3":[104],"nmol/L":[105,123],"on":[106],"isolated":[108],"enzyme.":[110],"compound":[112],"abrogates":[113],"etoposide-induced":[115],"G(2)":[116],"arrest":[117],"55":[122],"HT29":[125],"cells,":[126],"significantly":[128],"enhances":[129],"gemcitabine":[134,211],"SN38":[136],"by":[137,216],"3.0-":[138],"29-fold":[140],"several":[142],"colon":[143],"tumor":[144,206],"lines":[145],"vitro":[147,181],"p53-dependent":[151],"fashion.":[152],"Biomarker":[153],"studies":[154],"shown":[156],"inhibits":[159],"cytotoxic":[160],"drug-induced":[161],"autophosphorylation":[162],"S296":[166],"blocks":[168],"phosphorylation":[170],"CDK1":[172],"Y15":[174],"dose-dependent":[177],"fashion":[178],"both":[179],"vivo.":[184],"Cytotoxic":[185],"drug":[186],"combinations":[187],"were":[188],"increased":[191],"gammaH2AX":[192],"poly":[194],"ADP":[195],"ribose":[196],"polymerase":[197],"cleavage":[198],"consistent":[199],"SAR-020106-enhanced":[202],"death.":[208],"Irinotecan":[209],"activity":[213,235],"was":[214],"enhanced":[215],"vivo":[219,241],"minimal":[221],"toxicity.":[222],"represents":[224],"novel":[226],"class":[227],"inhibitors":[230],"can":[232],"selected":[237],"anticancer":[238],"therefore":[244],"clinical":[246],"utility.":[247]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2139291133","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":8},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":9},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":9},{"year":2014,"cited_by_count":11},{"year":2013,"cited_by_count":13},{"year":2012,"cited_by_count":13}],"updated_date":"2026-11-17T12:49:18.490984","created_date":"2016-06-24T00:00:00"}
